Compare VUZI & HELP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VUZI | HELP |
|---|---|---|
| Founded | 1997 | N/A |
| Country | United States | Canada |
| Employees | N/A | 50 |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 303.5M | 279.9M |
| IPO Year | 2009 | N/A |
| Metric | VUZI | HELP |
|---|---|---|
| Price | $4.57 | $4.55 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $51.50 |
| AVG Volume (30 Days) | ★ 2.7M | 694.2K |
| Earning Date | 05-08-2026 | 07-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 61.11 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $6,280,611.00 | N/A |
| Revenue This Year | $103.32 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 9.14 | N/A |
| 52 Week Low | $1.83 | $4.15 |
| 52 Week High | $5.62 | $8.55 |
| Indicator | VUZI | HELP |
|---|---|---|
| Relative Strength Index (RSI) | 65.78 | 43.72 |
| Support Level | $2.22 | $4.52 |
| Resistance Level | $5.62 | $6.26 |
| Average True Range (ATR) | 0.56 | 0.26 |
| MACD | 0.04 | 0.01 |
| Stochastic Oscillator | 71.81 | 38.67 |
Vuzix Corp is engaged in the design, manufacture, and marketing of Artificial Intelligence (AI)-powered Smart Glasses, Waveguides, and Augmented Reality (AR) technologies. Its solutions serve the enterprise, medical, defense, security, and select consumer markets, offering cutting-edge wearable computing and display technologies that enhance productivity and operational efficiency. Its products include near-eye displays (NEDs), heads-up displays (HUDs), and wearable computing devices and third-party original design manufacturer (ODM) and original equipment manufacturer (OEM) devices. Geographically, the company generates a majority of its revenue from the United States and also has a presence in Japan, the Netherlands, and other countries.
Helus Pharma Inc, the commercial operating name of Cybin Inc, is a clinical-stage pharmaceutical company focused on developing proprietary neuroactive compounds, referred to as NSAs, which are synthetic molecules designed to target serotonin pathways. The company's programs are aimed at treating mental health conditions such as depression and anxiety. Its pipeline includes HLP003, which is in clinical development for the adjunctive treatment of depressive disorder, and HLP004, which is in clinical development for generalized anxiety disorder. The company also conducts research on additional investigational compounds.